Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics' Data on Lead Candidate NS2 to be Presented at Society for Investigative Dermatology 2014 Annual Meeting
Results Suggest Novel Approach to Treating Dry Skin and Dry Eye Diseases
View HTML
Toggle Summary Aldeyra Therapeutics Announces Closing of Initial Public Offering of 1,500,000 Shares of Common Stock
BURLINGTON, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the closing of its previously announced initial public offering of
View HTML
Toggle Summary Aldeyra Therapeutics Prices Initial Public Offering of 1,500,000 Shares of Common Stock
BURLINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics ("Aldeyra"), a biotechnology company focused on the development of products to treat diseases where free aldehydes are thought to be important to the pathology, today announced the pricing of its initial public offering of
View HTML